#1 Clinical Trials Search in Europe

Siphoviridae Bacteriophage Against Pseudomonas Aeruginosa (43.020 Bp)

This article discusses a clinical trial investigating the use of a novel bacteriophage cocktail called TP-122A for treating ventilator-associated pneumonia (VAP). The study aims to assess the safety and effectiveness of this innovative therapy when used alongside standard care in adult patients with VAP caused by Pseudomonas aeruginosa infections.

Table of Contents

What is SIPHOVIRIDAE BACTERIOPHAGE AGAINST PSEUDOMONAS AERUGINOSA (43.020 BP)?

SIPHOVIRIDAE BACTERIOPHAGE AGAINST PSEUDOMONAS AERUGINOSA (43.020 BP) is a type of virus that specifically targets and kills the bacteria called Pseudomonas aeruginosa. This bacteriophage, also known by its synonym Psa_F95/13, is part of a new medication called TP-122 that is being studied to treat a serious lung infection called ventilator-associated pneumonia[1].

What is Ventilator-Associated Pneumonia (VAP)?

Ventilator-Associated Pneumonia (VAP) is a type of lung infection that occurs in people who are on mechanical ventilation breathing machines in hospitals. These machines are used to help a patient breathe, but they can also increase the risk of serious lung infections. VAP is particularly dangerous because the bacteria causing it, like Pseudomonas aeruginosa, can be resistant to many antibiotics[1].

Current Clinical Trial

A clinical trial is currently underway to test the safety and effectiveness of TP-122, which includes the SIPHOVIRIDAE BACTERIOPHAGE AGAINST PSEUDOMONAS AERUGINOSA (43.020 BP). This trial is called a Phase 1/2a study, which means it’s one of the earliest stages of testing a new treatment in humans[1].

The main goals of this trial are:

  • To check if TP-122 is safe to use in patients with VAP
  • To see how well patients tolerate the treatment
  • To find out if TP-122 helps cure the infection better than standard treatments alone

How Does It Work?

SIPHOVIRIDAE BACTERIOPHAGE AGAINST PSEUDOMONAS AERUGINOSA (43.020 BP) works by targeting and killing the Pseudomonas aeruginosa bacteria that cause VAP. Unlike traditional antibiotics, which can kill many types of bacteria (including helpful ones), bacteriophages are very specific. They only attack the particular type of bacteria they’re designed for[1].

In this clinical trial, TP-122 (which includes this bacteriophage) is given to patients through nebulization. This means the medication is turned into a fine mist that patients can inhale directly into their lungs where the infection is[1].

Who Can Participate in the Trial?

The trial is looking for adult patients (18 years or older) who have VAP caused by Pseudomonas aeruginosa. Some key eligibility criteria include:

  • Having a confirmed diagnosis of VAP
  • Being on a ventilator with stable breathing requirements
  • Having a confirmed Pseudomonas aeruginosa infection in the lungs

However, some people cannot participate, such as those with certain cancers, severe asthma, or who are pregnant or breastfeeding[1].

Safety and Side Effects

One of the main goals of this clinical trial is to assess the safety of TP-122. The researchers will be closely monitoring for any side effects or adverse events. They will be checking:

  • Any new symptoms or health issues that arise during treatment
  • Changes in laboratory test results
  • Changes in vital signs like heart rate and blood pressure
  • Changes in heart activity through ECG tests

It’s important to note that as this is an early-stage trial, not all potential side effects may be known yet[1].

Future Prospects

If this clinical trial shows that SIPHOVIRIDAE BACTERIOPHAGE AGAINST PSEUDOMONAS AERUGINOSA (43.020 BP), as part of TP-122, is safe and effective, it could lead to further studies and potentially a new treatment option for patients with VAP. This could be particularly important for patients with antibiotic-resistant infections[1].

However, it’s important to remember that this is still an experimental treatment. More research is needed to fully understand its effectiveness and safety. Patients should always consult with their healthcare providers about their treatment options[1].

Aspect Details
Study Type Phase 1/2a, randomized, parallel, open-label clinical trial
Investigational Product TP-122A (Siphoviridae Bacteriophage Against Pseudomonas Aeruginosa)
Target Condition Ventilator-Associated Pneumonia (VAP) caused by Pseudomonas aeruginosa
Primary Objective Evaluate safety and tolerability of TP-122A
Secondary Objectives Assess clinical cure rate, time to cure, microbiological response, mechanical ventilation duration, ICU stay
Administration Nebulization every 8 hours for 7 days, in addition to standard care
Key Inclusion Criteria Adults with VAP, stable ventilatory requirements, P. aeruginosa infection in lower respiratory tract
Key Exclusion Criteria Recent cancer treatment, severe respiratory conditions, immunocompromised status
Primary Endpoints Adverse events, clinical laboratory parameters, vital signs, ECG changes
Secondary Endpoints Clinical cure rate, time to cure, microbiological response, mechanical ventilation duration, ICU stay, survival

FAQ

  • What is TP-122A and how does it work? TP-122A is a bacteriophage cocktail containing Siphoviridae bacteriophages that target Pseudomonas aeruginosa. Bacteriophages are viruses that specifically infect and kill bacteria, potentially offering a new approach to treating bacterial infections.
  • Who is eligible for this clinical trial? The trial is open to adults (18 years or older) with ventilator-associated pneumonia caused by Pseudomonas aeruginosa. Participants must meet specific criteria related to their respiratory function and overall health status.
  • How is TP-122A administered in this study? TP-122A is administered through nebulization (inhaled as a mist) every 8 hours for 7 days, in addition to standard care treatment for VAP.
  • What are the main objectives of this clinical trial? The primary objective is to evaluate the safety and tolerability of TP-122A. Secondary objectives include assessing its effectiveness in treating VAP, measuring the time to clinical cure, and evaluating its impact on mechanical ventilation duration and ICU stay.
  • What potential benefits and risks are associated with participating in this trial? Potential benefits include access to a novel treatment for VAP. Risks may include adverse events related to the investigational product. The study closely monitors participants' safety through various assessments, including adverse event tracking, laboratory tests, vital signs, and ECG measurements.

Ongoing Clinical Trials on Siphoviridae Bacteriophage Against Pseudomonas Aeruginosa (43.020 Bp)

  • Safety and tolerability study of bacteriophage cocktail TP-122A given by inhalation in adults with ventilator-associated pneumonia

    Not yet recruiting

    2 1 1
    Investigated drugs:
    The Netherlands Portugal

  • Study on the Safety and Tolerability of TP-122 for Treating Ventilator-Associated Pneumonia in Adults

    Not yet recruiting

    2 1 1
    Investigated drugs:
    France

Glossary

  • Ventilator-Associated Pneumonia (VAP): A type of lung infection that occurs in people who are on mechanical ventilation breathing machines in hospitals.
  • Bacteriophage: A virus that specifically infects and replicates within bacteria, often killing the bacteria in the process.
  • Siphoviridae: A family of viruses that infect bacteria, characterized by their long, non-contractile tails.
  • Pseudomonas aeruginosa: A type of bacteria that can cause severe hospital-acquired infections, particularly in patients with weakened immune systems.
  • Nebulization: The process of converting a liquid into a fine spray or mist, often used to administer medications directly to the lungs.
  • Standard of Care (SoC): The currently accepted method of treating a particular condition, based on scientific evidence and expert consensus.
  • Adverse Event (AE): Any unfavorable and unintended sign, symptom, or disease temporarily associated with the use of a medical treatment or procedure.
  • Clinical Cure: The resolution or significant improvement of signs and symptoms related to the infection being treated.
  • Microbiological Response (MR): The effect of treatment on the presence of bacteria in the body, often measured by laboratory tests.
  • Intensive Care Unit (ICU): A specialized hospital department that provides intensive care medicine to critically ill patients.

References

  1. http://clinicaltrials.eu/trial/study-on-the-safety-and-tolerability-of-tp-122-for-treating-ventilator-associated-pneumonia-in-adults/